This document presents a strategic framework, aimed towards the development of sustainable global, regional and national plans relating to laboratory biorisk management.
Q7. SCOPING QUESTION: In adults with moderate-severe depressive disorder, what is the effectiveness and safety of antidepressant medication (ADM) in comparison with psychological treatment?
The WHO mhGAP programme’s existing guidelines recommend that either structured brief psychological treatm...ents (e.g., interpersonal psychotherapy or cognitive behavioural therapy, including behavioural activation) or antidepressant medication (e.g., SSRIsi and tricyclic antidepressants) be considered in adults with moderate-severe depression. Health care workers need to know whether these treatments have different effects, including side-effects, in treating depressive disorder in the short and long term, in order to improve clinical decision-making.
more
This Training Manual is developed based on the Child Protection Working Group Interagency Guidelines for Case Management. The Facilitator’s Guide provides guidance on the key steps to take before, during and after training, including customizing the training to different contexts and audiences.
BMJ 2020;368:m1052 doi: 10.1136/bmj.m1052 (Published 13 March 2020)
This document is the third iteration of the Flash Appeal for Ukraine, which was originally published on 1 March 2022 and revised once in mid-April. This updated Flash Appeal covers the period of 10 months following the onset of the war in Ukraine that started on 24 February 2022 (i.e., from March to... December 2022). The financial requirement of this Flash Appeal reflects the humanitarian needs from March until the end of 2022, taking into account the funding status and the response achievements to date, as well as the realistic projection of response capacity in the second half of the year.
more
A Resource Guide for Country Offices
Recommandations francaises pour la prise enc harge du chikungunya
Médecine e tmaladies infectieuses 45(2015)243–263
Key Populations Brief
Accessed November 2017
These WHO interim recommendations on the use of the Pfizer – BioNTech BNT162b2 vaccine against Covid-19 were developed on the basis of advice issued by the Strategic Advisory Group of Experts on Immunization (SAGE) and the evidence summary included in the background document referenced below.
fir...st issued 8 January 2021, updated 15 June 2021, updated 19 November 2021, updated 21 January 2022, updated 18 August 2022. Available in other languages https://apps.who.int/iris/handle/10665/361720
more
Canadian Journal of Microbiology 25 June 2021 https://doi.org/10.1139/cjm-2020-0572